Cargando…

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

Introduction: This study sought to estimate the global prevalence of transthyretin familial amyloid polyneuropathy (ATTR‐FAP). Methods: Prevalence estimates and information supporting prevalence calculations was extracted from records yielded by reference‐database searches (2005–2016), conference pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Hartmut H., Waddington‐Cruz, Márcia, Botteman, Marc F., Carter, John A., Chopra, Avijeet S., Hopps, Markay, Stewart, Michelle, Fallet, Shari, Amass, Leslie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Basic Science Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947118/ https://www.ncbi.nlm.nih.gov/pubmed/29211930 http://dx.doi.org/10.1002/mus.26034

Ejemplares similares

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
por: Waddington-Cruz, Márcia, et al.
Publicado: (2019)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
por: Keohane, Denis, et al.
Publicado: (2015)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington-Cruz, Márcia, et al.
Publicado: (2021)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
por: Amass, Leslie, et al.
Publicado: (2018)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Transthyretin interacts with actin regulators in a Drosophila model of familial amyloid polyneuropathy
por: I. Oliveira da Silva, Marina, et al.
Publicado: (2020)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)
por: Ferreira, Natália
Publicado: (2015)

Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy
por: Lopes, Alice, et al.
Publicado: (2017)

Nerve Ultrasound Comparison Between Transthyretin Familial Amyloid Polyneuropathy and Chronic Inflammatory Demyelinating Polyneuropathy
por: Du, Kang, et al.
Publicado: (2021)

Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
por: Mariani, Louise‐Laure, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017)

Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China
por: Liu, Lei, et al.
Publicado: (2020)

Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics
por: Du, Kang, et al.
Publicado: (2022)

Inflammatory profiling of patients with familial amyloid polyneuropathy
por: Azevedo, Estefania P., et al.
Publicado: (2019)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy
por: Warendorf, Janna K., et al.
Publicado: (2023)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Suenaga, Genki, et al.
Publicado: (2017)

Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas
por: Thimm, Andreas, et al.
Publicado: (2019)

Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer
por: Cotrina, Ellen Y., et al.
Publicado: (2020)

Vagus nerve ultrasound in transthyretin familial amyloid polyneuropathy: A pilot study
por: Du, Kang, et al.
Publicado: (2021)

Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care
por: Adams, David
Publicado: (2016)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center
por: Sequeira, Vanessa Cristina Cunha, et al.
Publicado: (2021)

Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study
por: Reinés, Juan Buades, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jqckn5bq4p7v4vf34uvq4e6hio